Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Showcased Phase III ADC Data, Is It A Bargain?

Simply Wall St.10-17

Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) just presented new clinical data for its antibody-drug conjugate sacituzumab tirumotecan to a global oncology audience, including several Phase III ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2676544447?lang=en_US&edition=fundamental","thumbnail":"https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532","is_english":true,"pubTime":"2026-10-17 17:35","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2676544447","market":"nz","top_or_hot":-1,"title":"Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Showcased Phase III ADC Data, Is It A Bargain?","media":"Simply Wall St.","content":"<div>\n<p>Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) just presented new clinical data for its antibody-drug conjugate sacituzumab tirumotecan to a global oncology audience, including several Phase III ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelun-biotech-biopharmaceutical-sehk6990-showcased-p\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Sichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Showcased Phase III ADC Data, Is It A Bargain?</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSichuan Kelun Biotech Biopharmaceutical (SEHK:6990) Showcased Phase III ADC Data, Is It A Bargain?\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-10-17 17:35 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelun-biotech-biopharmaceutical-sehk6990-showcased-p><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) just presented new clinical data for its antibody-drug conjugate sacituzumab tirumotecan to a global oncology audience, including several Phase III ...</p>\n\n<a href=\"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelun-biotech-biopharmaceutical-sehk6990-showcased-p\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4588","symbol_name":"碎股","start_time":0,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelun-biotech-biopharmaceutical-sehk6990-showcased-p","article_id":"2676544447","we_media_id":null,"thumbnails":["https://simplywall.st/cdn-cgi/image/fit=cover,format=auto,width=320,height=180/https://images.simplywall.st/asset/industry/6111000-choice1-card/1788937617532"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-6990/sichuan-kelun-biotech-biopharmaceutical-shares/news/sichuan-kelun-biotech-biopharmaceutical-sehk6990-showcased-p","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2676544447","pubTimestamp":1792229746,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) just presented new clinical data for its antibody-drug conjugate sacituzumab tirumotecan to a global oncology audience, including several Phase III readouts selected for high-profile oral sessions.\nThe new clinical readouts arrive as Sichuan Kelun-Biotech Biopharmaceutical trades at HK$452.0, with a 1-day share price return of 3.10% and a year-to-date share price return of 12.83%. The 1-year total shareholder return is slightly negative,...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4588":"碎股","BK4585":"ETF&股票定投概念","BK1161":"生物科技","LU0196878994.USD":"MANULIFE GF CHINA VALUE \"AA\" (USD) INC","BK4581":"高盛持仓","06990":"科伦博泰生物","XBI":"SPDR S&P Biotech ETF"},"translate_title":"四川科伦生物生物制药（SEHK:6990）展示III期ADC数据，划算吗？","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"06990":0.9,"XBI":1.5},"content_text":"Sichuan Kelun-Biotech Biopharmaceutical (SEHK:6990) just presented new clinical data for its antibody-drug conjugate sacituzumab tirumotecan to a global oncology audience, including several Phase III readouts selected for high-profile oral sessions. The new clinical readouts arrive as Sichuan Kelun-Biotech Biopharmaceutical trades at HK$452.0, with a 1-day share price return of 3.10% and a year-to-date share price return of 12.83%. The 1-year total shareholder return is slightly negative, while the 3-year total shareholder return is a very large multiple. This suggests that long term holders have already seen substantial value created even as shorter term momentum has recently cooled. Spot emerging oncology players moving on fresh trial data by scanning the 127 healthcare AI stocks that could sit alongside Sichuan Kelun-Biotech Biopharmaceutical in a high-conviction watchlist.\nBulls point to sac-TMT’s approvals, the global MSD partnership and very large 3-year shareholder gains. Bears flag the recent share price pullback and modest 1-year decline. Which story does Sichuan Kelun-Biotech Biopharmaceutical’s current valuation actually tell? AdvertisementMost Popular Narrative: 27% Undervalued Against a last close of HK$452.0, the most followed narrative pegs Sichuan Kelun-Biotech Biopharmaceutical’s fair value at HK$618.43, using a 7.3% discount rate and long range earnings assumptions to bridge the gap. Kelun Biotech is leaning heavily on long duration oncology trends such as wider ADC use, combination regimens with immunotherapies and large global Phase III programs with partners like MSD. Together, these create meaningful optionality for new indications, overseas launches and royalty streams that could shift earnings and market expectations away from a flat share price if more products reach approval and commercialization. See why 1 investors see Sichuan Kelun-Biotech Biopharmaceutical as 27% undervalued. Result: Fair Value of HK$618.43 (UNDERVALUED) Still, the analysts’ story for Sichuan Kelun-Biotech Biopharmaceutical can break if Phase III trials disappoint or key partners slow milestones and royalty payments. Find out about the key risks to this Sichuan Kelun-Biotech Biopharmaceutical narrative. Another View: What The P/S Ratio Signals For Sichuan Kelun-Biotech Biopharmaceutical The DCF story is one thing. On a simple P/S yardstick, Sichuan Kelun-Biotech Biopharmaceutical trades on 44.2x sales, while the Hong Kong biotech group sits around 8.9x and the fair ratio is 15.2x. That is a wide gap. Is it a premium that future execution can actually justify? See what the numbers say about this price — find out in our valuation breakdown. SEHK:6990 P/S Ratio as at Oct 2026Next Steps Mixed signals around Sichuan Kelun-Biotech Biopharmaceutical’s valuation and expectations only matter if you pressure test them yourself and decide where you stand. Act while the data and sentiment are fresh by reviewing the 4 key rewards and 1 important warning sign. Looking For More Investment Ideas Beyond Sichuan Kelun-Biotech Biopharmaceutical? If Sichuan Kelun-Biotech Biopharmaceutical is already on your radar, rounding out your watchlist with a few different angles can sharpen your decision making and keep you ahead.  Target potential mispricings by scanning a curated pool of stocks that trade below their assessed fair value using the 191 high quality undervalued stocks. Build resilience into your portfolio by reviewing a list of solid balance sheet and fundamentals (203 results) that can help anchor returns when conditions become more volatile. Get in early on future contenders by surveying 618 high quality undiscovered gems that pair strong fundamentals with relatively low market attention.   This article by Simply Wall St is general in nature. We provide commentary based on historical data\n        and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n        financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n        Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n        Simply Wall St has no position in any stocks mentioned.New: Manage All Your Stock Portfolios in One PlaceWe've created the ultimate portfolio companion for stock investors, and it's free.• Connect an unlimited number of Portfolios and see your total in one currency• Be alerted to new Warning Signs or Risks via email or mobile• Track the Fair Value of your stocksTry a Demo Portfolio for FreeHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":false,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2676544447","isCrawlerRequest":true}